Waiting for regulatory approvals for Suven CRAMS demerger process: Venkat Jasti, Suven Life Sciences
  • WebDesk BTVI
  • Jun 20 2019

Venkat Jasti, Chairman & MD, Suven Life Sciences, says they were waiting for regulatory approvals for Suven CRAMS demerger process, expects a growth in range of 20-25% for FY20, also expects speciality business growth to be in the same range as that of last year.